These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30977836)

  • 21. Measuring humanized antibodies in plasma of patients treated with antibody-based therapy using bead-based flow cytometry: the story of alemtuzumab.
    Chan HE; Jilani I; Chang R; Albitar M
    Methods Mol Biol; 2007; 378():159-65. PubMed ID: 18605084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.
    Lambert C; Dubois B; Dive D; Lysandropoulos A; Selleslag D; Vanopdenbosch L; Van Pesch V; Vanwijmeersch B; Janssens A
    Acta Neurol Belg; 2018 Mar; 118(1):7-11. PubMed ID: 29380254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
    Prescrire Int; 2015 Mar; 24(158):69. PubMed ID: 25897458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.
    Jones DE; Goldman MD
    Expert Rev Clin Immunol; 2014 Oct; 10(10):1281-91. PubMed ID: 25148422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alemtuzumab and multiple sclerosis: therapeutic application.
    Minagar A; Alexander JS; Sahraian MA; Zivadinov R
    Expert Opin Biol Ther; 2010 Mar; 10(3):421-9. PubMed ID: 20095876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
    Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab treatment of multiple sclerosis.
    Coles AJ
    Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
    Buonomo AR; Saccà F; Zappulo E; De Zottis F; Lanzillo R; Gentile I; Carotenuto A; Borgia G; Russo CV
    Mult Scler Relat Disord; 2019 Jan; 27():44-45. PubMed ID: 30316174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alemtuzumab treatment for Sézary syndrome: A single-center experience.
    Novelli S; García-Muret P; Sierra J; Briones J
    J Dermatolog Treat; 2016; 27(2):179-81. PubMed ID: 26329989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alemtuzumab: what is the secret to safe therapy?
    Elter T; Hallek M; Montillo M
    Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy (alemtuzumab).
    Clark SL; Tse JY; Fisher DC; LeBeouf NR; Murphy GF; Kupper TS; Clark RA; Lian CG
    J Cutan Pathol; 2016 Nov; 43(11):989-993. PubMed ID: 27531597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
    Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
    CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience.
    Mohammad AJ; Smith RM; Chow YW; Chaudhry AN; Jayne DR
    J Rheumatol; 2015 Oct; 42(10):1906-13. PubMed ID: 26276966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical recommendations on the use of alemtuzumab (lemtrada)].
    Alifirova VM; Bisaga GN; Boyko AN; Bryukhov VV; Davydovskay MV; Zakharova MN; Zakharova EV; Malkova NA; Popova EV; Salogub GN; Sivertseva SA; Troshina EA; Khachanova NV; Schmidt TE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):115-126. PubMed ID: 28617370
    [No Abstract]   [Full Text] [Related]  

  • 38. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
    Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
    PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Giovannoni G; Cohen JA; Coles AJ; Hartung HP; Havrdova E; Selmaj KW; Margolin DH; Lake SL; Kaup SM; Panzara MA; Compston DA;
    Neurology; 2016 Nov; 87(19):1985-1992. PubMed ID: 27733571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.